中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
The Chinese Journal of Clinical Pharmacology
2015年
19期
1919-1921
,共3页
雷贝拉唑%胃癌%抑酸活性%Warburg效应
雷貝拉唑%胃癌%抑痠活性%Warburg效應
뢰패랍서%위암%억산활성%Warburg효응
rabeprazole%gastric cancer%activity of anti-acid%effect of Warburg
目的 探讨雷贝拉唑的抑酸活性对提高胃癌化疗的效果以及其最佳给药时间. 方法 将30例胃癌患者随机分为对照组、试验A组和试验B组,每组10例. 对照组予以口服2000 mg? m-2? d-1卡培他滨,每日2次,第1~14天加静脉滴注130 mg? m-2? d-1奥沙利铂,第1天;试验A组在对照组的基础上,加用口服雷贝拉唑20 mg,每天1次,第1~14天;试验B组在对照组的基础上,加用口服雷贝拉唑20 mg,每天1次,第-7~13天(即在化疗药开始前7天即开始使用). 3组患者均接受2个周期的治疗,每个周期21 d. 比较3组患者治疗后的临床疗效和不良反应发生率. 结果 对照组、试验A组、试验B组的有效率分别为 25.00%, 33.33%和 30.00%,疾病控制率分别为 62.50%、77.78%和70.00%,组间比较差异无统计学意义( P>0.05 ) ,但试验组的有效率和疾病控制率较对照组呈增高的趋势. 治疗期间,3组患者的主要不良反应为消化道反应、血液学毒性和手足综合征,但组间比较差异无统计学意义( P>0.05 ). 试验A组与试验 B 组的雷贝拉唑血药浓度比较差异无统计学意义( P >0.05 ).结论 卡培他滨联合奥沙利铂的临床疗效较好,不良反应较轻,雷贝拉唑提前1d给药即可达稳态.
目的 探討雷貝拉唑的抑痠活性對提高胃癌化療的效果以及其最佳給藥時間. 方法 將30例胃癌患者隨機分為對照組、試驗A組和試驗B組,每組10例. 對照組予以口服2000 mg? m-2? d-1卡培他濱,每日2次,第1~14天加靜脈滴註130 mg? m-2? d-1奧沙利鉑,第1天;試驗A組在對照組的基礎上,加用口服雷貝拉唑20 mg,每天1次,第1~14天;試驗B組在對照組的基礎上,加用口服雷貝拉唑20 mg,每天1次,第-7~13天(即在化療藥開始前7天即開始使用). 3組患者均接受2箇週期的治療,每箇週期21 d. 比較3組患者治療後的臨床療效和不良反應髮生率. 結果 對照組、試驗A組、試驗B組的有效率分彆為 25.00%, 33.33%和 30.00%,疾病控製率分彆為 62.50%、77.78%和70.00%,組間比較差異無統計學意義( P>0.05 ) ,但試驗組的有效率和疾病控製率較對照組呈增高的趨勢. 治療期間,3組患者的主要不良反應為消化道反應、血液學毒性和手足綜閤徵,但組間比較差異無統計學意義( P>0.05 ). 試驗A組與試驗 B 組的雷貝拉唑血藥濃度比較差異無統計學意義( P >0.05 ).結論 卡培他濱聯閤奧沙利鉑的臨床療效較好,不良反應較輕,雷貝拉唑提前1d給藥即可達穩態.
목적 탐토뢰패랍서적억산활성대제고위암화료적효과이급기최가급약시간. 방법 장30례위암환자수궤분위대조조、시험A조화시험B조,매조10례. 대조조여이구복2000 mg? m-2? d-1잡배타빈,매일2차,제1~14천가정맥적주130 mg? m-2? d-1오사리박,제1천;시험A조재대조조적기출상,가용구복뢰패랍서20 mg,매천1차,제1~14천;시험B조재대조조적기출상,가용구복뢰패랍서20 mg,매천1차,제-7~13천(즉재화료약개시전7천즉개시사용). 3조환자균접수2개주기적치료,매개주기21 d. 비교3조환자치료후적림상료효화불량반응발생솔. 결과 대조조、시험A조、시험B조적유효솔분별위 25.00%, 33.33%화 30.00%,질병공제솔분별위 62.50%、77.78%화70.00%,조간비교차이무통계학의의( P>0.05 ) ,단시험조적유효솔화질병공제솔교대조조정증고적추세. 치료기간,3조환자적주요불량반응위소화도반응、혈액학독성화수족종합정,단조간비교차이무통계학의의( P>0.05 ). 시험A조여시험 B 조적뢰패랍서혈약농도비교차이무통계학의의( P >0.05 ).결론 잡배타빈연합오사리박적림상료효교호,불량반응교경,뢰패랍서제전1d급약즉가체은태.
Objective To investigate whether rabeprazole could increase the sensitivity of chemotherapy on gastric cancer and to evaluate the opti-mal time of drug administration .Methods Thirty patients with gastric cancer were enrolled into the study and divided into three groups:control group and treatment group A and B , 10 patients in each group .Patients in control group were received:capecitabine 2000 mg? m-2? d-1 divide to twice a day, oral on day 1-14, oxaliplatin 130 mg? m-2? d-1 ivgtt on day 1.The treatment group A and B administrate rabeprazole 20 mg qd on day 1-14 and day -7-13 , respectively , on the basis of control group′s treatment.Twenty-one days was one cycle , 2 cycles for each group.Clinical efficacy and adverse drug reactions after two cycles in three groups were evaluated .Results The response rate of the control group , treatment group A and treatment group B were 25.00%, 33.33%and 30.00% respectively , the disease control rate were 62.50%, 77.78% and 70.00% respectively , there were no significat difference among three groups on the effect of chemotherapy .The response rate and the disease control rate of the treatment group were higher than those ofthe control group.The main adverse drug reactions during the treatment were gastrointestinal reaction , hematological toxicity and hand foot syndrome , and there was no statistic difference among three groups ( P>0.05 ).The plasma con-centration of rabeprazole between two treatment groups was no statistic difference ( P>0.05 ).Conclusion The clini-cal icacy of this chemotherapy ( capecitabine +oxaliplatin ) is better and the adverse drug reactions are less .Plasma concentration of rabeprazole could reach steady state in one day after drug administration .
